Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites
- 19 April 2017
- journal article
- clinical trial
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (9)
Abstract
Background: Hepatic sinusoidal obstruction syndrome (SOS) during treatment of childhood acute lymphoblastic leukemia (ALL) has mainly been associated with 6‐thioguanine. The occurrence of several SOS cases after the introduction of extended pegylated asparaginase (PEG‐asparaginase) therapy in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol led us to hypothesize that PEG‐asparaginase, combined with other drugs, may trigger SOS during 6‐thioguanine‐free maintenance therapy.Procedure: In children with ALL treated in Denmark according to the NOPHO ALL2008 protocol, we investigated the risk of SOS during methotrexate (MTX)/6‐mercaptopurine (6MP) maintenance therapy that included PEG‐asparaginase until week 33 (randomized to two‐ vs. six‐week intervals), as well as alternating high‐dose MTX or vincristine/dexamethasone pulses every four weeks.Results: Among 130 children receiving PEG‐asparaginase biweekly, 29 developed SOS (≥2 criteria: hyperbilirubinemia, hepatomegaly, ascites, weight gain ≥2.5%, unexplained thrombocytopenia 9 l–1) at a median of 30 days (interquartile range [IQR]: 17–66) into maintenance (cumulative incidence: 27%). SOS cases fulfilling one, two, or three Ponte di Legno criteria were classified as possible (n = 2), probable (n = 8), or verified (n = 19) SOS, respectively. Twenty‐six cases (90%) occurred during PEG‐asparaginase treatment, including 21 (81%) within 14 days from the last chemotherapy pulse compared with the subsequent 14 days (P = 0.0025). Cytotoxic 6MP metabolites were significantly higher on PEG‐asparaginase compared to after its discontinuation. Time‐dependent Cox regression analysis showed increased SOS hazard ratio (HR) for erythrocyte levels of methylated 6MP metabolites (HR: 1.09 per 1,000 nmol/mmol hemoglobin increase, 95% confidence interval: 1.05–1.14). Six‐week PEG‐asparaginase intervals significantly reduced SOS‐specific hazards (P < 0.01).Conclusions: PEG‐asparaginase increases cytotoxic 6MP metabolite levels and risk of SOS, potentially interacting with other chemotherapy pulses.Keywords
Funding Information
- Børnecancerfonden
This publication has 37 references indexed in Scilit:
- Liquid chromatography–tandem mass spectrometry quantification of 6-thioguanine in DNA using endogenous guanine as internal standardJournal of Chromatography B, 2012
- Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemiaLeukemia, 2011
- Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemiaPediatric Blood & Cancer, 2010
- Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trialBlood, 2010
- Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and OutcomeTransplantation and Cellular Therapy, 2010
- Advances in individual prediction of methotrexate toxicity: a reviewBritish Journal of Haematology, 2009
- Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trialThe Lancet, 2006
- Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92Blood, 2003
- Toxic Injury to Hepatic Sinusoids: Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease)Seminars in Liver Disease, 2002
- Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing FactorsHepatology, 1984